Find information on thousands of medical conditions and prescription drugs.

DDAVP

Desmopressin (DDAVP®, Stimate®, Minrin®) is a synthetic drug that mimics the action of antidiuretic hormone, also known as arginine vasopressin. It may be taken nasally, intravenously, or through a recently developed pill. more...

Home
Diseases
Medicines
A
B
C
D
Dacarbazine
Dactinomycin
Dalmane
Danazol
Dantrolene
Dapoxetine
Dapsone
Daptomycin
Daraprim
Darvocet
Darvon
Daunorubicin
Daunorubicin
Daypro
DDAVP
Deca-Durabolin
Deferoxamine
Delsym
Demeclocycline
Demeclocycline
Demerol
Demulen
Denatonium
Depakene
Depakote
Depo-Provera
Desferal
Desflurane
Desipramine
Desmopressin
Desogen
Desogestrel
Desonide
Desoxyn
Desyrel
Detrol
Dexacort
Dexamethasone
Dexamfetamine
Dexedrine
Dexpanthenol
Dextran
Dextromethorphan
Dextromoramide
Dextropropoxyphene
Dextrorphan
Diabeta
Diacerein
Diacetolol
Dial
Diamox
Diazepam
Diazoxide
Dibenzepin
Diclofenac
Diclohexal
Didanosine
Dieldrin
Diethylcarbamazine
Diethylstilbestrol
Diethyltoluamide
Differin
Diflucan
Diflunisal
Digitoxin
Digoxin
Dihydrocodeine
Dihydroergotamine
Dihydrotachysterol
Dilantin
Dilaudid
Diltahexal
Diltiazem
Dimenhydrinate
Dimercaprol
Dimetapp
Dimethyl sulfoxide
Dimethyltryptamine
Dimetridazole
Diminazene
Diovan
Dioxybenzone
Diphenhydramine
Diphenoxylate
Dipipanone
Dipivefrine
Diprivan
Diprolene
Diproteverine
Dipyridamole
Disulfiram
Disulfiram
Dizocilpine
Dobutamine
Docetaxel
Docusate sodium
Dofetilide
Dolasetron
Dolobid
Dolophine
Domperidone
Donepezil
Dopamine
Dopram
Doral
Doramectin
Doriden
Dornase alfa
Doryx
Dostinex
Doxapram
Doxazosin
Doxepin
Doxil
Doxil
Doxorubicin
Doxy
Doxycycline
Doxyhexal
Doxylamine
Drisdol
Drixoral
Dronabinol
Droperidol
Drospirenone
Duloxetine
Durabolin
Duragesic
Duraphyl
Duraquin
Dutasteride
Dv
Dyclonine
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Chemistry

Desmopressin (1-desamino-8-d-arginine vasopressin) is a modified form of the normal human hormone arginine vasopressin, an octapeptide (a chain of eight amino acids).

Compared to vasopressin, desmopressin's first amino acid has been deaminated, and the arginine at the eighth position is in the levo rather than the dextro form (see stereochemistry).

Method of action

Desmopressin binds to V2 receptors in renal collecting ducts, increasing water resorption. It also stimulates release of factor VIII from platelets due to stimulation of the V1a receptor.

Desmopressin is degraded more slowly than recombinant vasopressin, and requires less frequent administration. In addition, it has little effect on blood pressure, while vasopressin may cause arterial hypertension.

Uses

Desmopressin is used to reduce urine production in central diabetes insipidus patients and to promote the release of von Willebrand factor and factor VIII in patients with coagulation disorders such as type I von Willebrand disease, hemophilia A, and thrombocytopenia. Desmopressin is not effective in the treatment of hemophilia B.

It may also be prescribed to reduce frequent bedwetting episodes in children by decreasing noctural urine production.

Side effects

  • headaches
  • facial flushing
  • nausea

Read more at Wikipedia.org


[List your site here Free!]


Protect, defend … and keep moving ahead
From Food & Drug Packaging, 7/1/05 by Lisa McTigue Pierce

The August 2004 merger of French pharmaceutical giants Sanofi-Synthelabo and Aventis created the third largest pharmaceutical company in the world: sanofi-aventis.

Don't let the lowercase treatment fool you, sanofi-aventis is not a quiet company abroad. It ranks No. 1 in Europe. And, with the Aventis merger, it's poised to make noise in the U.S. The company conducts its business here through its subsidiaries Sanofi Synthelabo Inc., Aventis Pharmaceuticals Inc. and Sanofi Pasteur Inc. sanofi-aventis concentrates on drug development in seven areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. The last business got a boost from strong U.S. sales in late 2004 when rival Chiron failed to deliver enough flu shots. Fourth-quarter sales of sanofi-aventis' flu vaccine were up 70% over the same period in 2003.

Among its leading brands are allergy relief medicine Allegra, Plavix (marketed in the U.S. by Bristol-Myers Squibb), Lovenox, Ambien and Actonel (with Procter & Gamble Pharmaceuticals).

Like other big pharma companies, sanofi-aventis faces competition from generics. (The company is focusing on its own generic business for the European market.) The FDA recently approved generic equivalents of two of the company's drugs:

* Teva Pharmaceuticals Industries Ltd. will market a generic version of sanofi-aventis' anti-diabetic treatment Amaryl, which was nearing patent expiration anyway.

* Barr Laboratories is launching a generic version of DDAVP, an anti-diuretic sold by Aventis.

Despite these setbacks, business is good and probably will get better. Market analysts have described the company's pipeline as the "best in the industry." It has 128 products in development, including 48 entities in phase II or III clinical trial.

Two new drugs have the potential to reach blockbuster status: Exubera and Acomplia.

* In March 2005, sanofi-aventis and Pfizer filed a New Drug Application (NDA) for Exubera. It's the first dry-powder inhalation insulin drug for treating diabetes that's been submitted to the FDA.

* In June 2005, sanofi-aventis released results from the final clinical trials of Acomplia. Billed as a wonder drug, Acomplia is a weight-loss pill that also helps control blood sugar levels for diabetes treatment. It works by blocking hunger-inducing receptors in the brain and, in fat tissue, increasing the protein cytokine. When people don't have enough cytokine, it interferes with their insulin levels, putting them at higher risk of developing type 2 diabetes. And, because the area of the brain that controls hunger also controls other addictive behaviors, Acomplia may also help people stop smoking cigarettes.

These successes bode well for sanofi-aventis, but the company hasn't been without corresponding battles. It fiercely protects its intellectual properties by defending its patents in the courts--a practice that executives vow will continue. Last month, a U.S. court ruled in favor of generic producer Amphastar Pharmaceuticals in a trial alleging patent infringement of sanofi-aventis' Lovenox, sanofi-aventis is appealing that decision.

The company's strategy? Move promising products forward through the pipeline and force competitors to try to keep up.

COPYRIGHT 2005 Stagnito Communications
COPYRIGHT 2005 Gale Group

Return to DDAVP
Home Contact Resources Exchange Links ebay